Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 15, 2017
Preclinical Research Demonstrating a Relationship Between Amyloid Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP and Health-related Quality of Life DUBLIN, Irelan...
Aug 8, 2017
Net cash used in operating and investing activities was $36.3 million in the second quarter and $76.5 million for the first six months of 2017; quarter-end cash and restricted cash position of $475.8 million, provides funding to advance diverse pipelineInitiated, with Roche, the global Phase 2 PASADENA st...
Aug 1, 2017
DUBLIN, Ireland, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the second quarter and first six months of 2017 on August 8, 2...
Jul 5, 2017
First potentially disease-modifying anti-alpha-synuclein antibody to be evaluated for efficacy in patients with Parkinson's diseaseProthena to receive $30 million milestone payment under collaboration agreement with Roche DUBLIN, Ireland, July 05, 2017 (GLOBE...
Jun 12, 2017
DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Wagner Zago, PhD, as Chief Scientific Officer (CSO). Dr. Zago, wh...
May 16, 2017
DUBLIN, Ireland, May 16, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Sarah Noonberg, MD, PhD, as Chief Medical Officer. Dr. Noonberg ...
May 9, 2017
Net cash used in operating and investing activities was $40.2 million in the first quarter; quarter-end cash and restricted cash position of $510.6 million, including net proceeds of $150.3 million raised through March 2017 public equity offering, provides funding to advance R&D pipelineCompleted enro...
May 2, 2017
DUBLIN, Ireland, May 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the first quarter of 2017 on May 9, 2017 after the close of the U.S. financial ...
Apr 26, 2017
DUBLIN, Ireland, April 26, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Deutsche Bank 42nd...
Apr 2, 2017
All dose levels of PRX002/RG7935 found to have an acceptable safety and tolerability profile, meeting the primary objective of this studyRobust central nervous system (CNS) penetration demonstrated by a dose-dependent increase in PRX002 levels in cerebrospinal fluid (CSF), and mean concentrati...
Mar 9, 2017
Investor webcast planned for April 2, 2017 at 9:00 AM EDT to discuss Phase 1b study results  Prothena and Roche to co-host symposium on alpha-synuclein pathology and non-motor manifestations in Parkinson's disease on March 31, 2017 at 5:15 CET DUBLIN, I...
Mar 3, 2017
DUBLIN, Ireland, March 03, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has sold 2,700,000 of its ordinary shares at a price to the public of $57...
Mar 2, 2017
DUBLIN, Ireland, March 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has commenced a registered underwritten public offering of 2,700,000 of its ordinary shar...
Feb 14, 2017
Net cash used in operating and investing activities was $41.1 million in the fourth quarter and $133.9 million for the full year 2016; year-end cash and restricted cash position of $391 million supports advancement of clinical pipeline         Pre...
Feb 8, 2017
DUBLIN, Ireland, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the Lee...
Feb 1, 2017
DUBLIN, Ireland, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2016 financial results on Tue...
Jan 4, 2017
DUBLIN, Ireland, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in the 35th A...
Dec 15, 2016
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Carol D. Karp as Chief Regulatory Officer. Ms. Karp will lead P...
Dec 13, 2016
DUBLIN, Ireland, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced the ...
Nov 9, 2016
All dose levels of PRX002 found to have an acceptable safety and tolerability profile, meeting the primary objective of this studyRobust central nervous system (CNS) penetration demonstrated by a dose-dependent increase in PRX002 levels in cerebrospinal fluid (CSF), and mean concentration of...
Nov 3, 2016
DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its NEOD001 Phase 1/2 dose-escalation and expansion study will be highligh...
Nov 1, 2016
Net cash used in operating and investing activities was $39.1 million in the third quarter and $96.8 million for the first nine months of 2016; quarter-end cash and restricted cash position of $412.6 million supports advancement of a diverse pipeline and commercial capabilities...
Oct 25, 2016
DUBLIN, Ireland, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the third quarter and first nine months of 2016 on November 1, 2016 after the ...
Oct 3, 2016
DUBLIN, Ireland, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that Gene Kinney, PhD has been appointed President and Chief Executive Officer of ...
Sep 30, 2016
DUBLIN, Ireland, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), announced today that its Co-founder, President and Chief Executive Officer, Dr. Dale B. Schenk, passed away this morning, after confronting his pancreatic cancer with the same courage, determination and humor that pervaded all areas of...
Sep 29, 2016
Investor conference call and webcast planned today at 4:30 PM ET DUBLIN, Ireland, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein ...
Sep 26, 2016
DUBLIN, Ireland, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that its President and Chief Executive Officer Dale Schenk, PhD, who announced in December 2014 ...
Sep 22, 2016
DUBLIN, Ireland, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its management team will discuss the Phase 2 development strateg...
Sep 6, 2016
DUBLIN, Ireland, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced the promotion of Gene G. Kinney, PhD to the position of Chief Operating Officer ...
Aug 30, 2016
DUBLIN, Ireland, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in several upcoming investo...
Aug 2, 2016
Net cash used in operating and investing activities was $32.3 million in the second quarter and $57.7 million for the first six months of 2016; strong quarter-end cash and restricted cash position of $447.0 million supports advancement of multiple clinical development programsPresented new cli...
Jul 6, 2016
DUBLIN, Ireland, July 06, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in Cantor ...
Jul 5, 2016
New data from Phase 1/2 dose-escalation (n=27) and expansion (n=42) study show best response rates in total cardiac- and renal- evaluable patients of 53% and 63%, respectively, that are consistent with those previously published in the Journal of Clinical OncologyImprovement of periphera...
Jun 21, 2016
New clinical data to be presented from Phase 1/2 dose-escalation and expansion trial of NEOD001 for the potential treatment of AL amyloidosisPresentations to highlight data from clinical, preclinical and quality-of-life studiesInvestor webcast planned for July 5, 2016...
Jun 9, 2016
All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteersNeutralization of Th17 cells of greater than 95 percent and statistically significant  dose-dependent duration of MCAM downregulation obse...
May 23, 2016
New clinical data to be presented from expansion cohort of Phase 1/2 trial of NEOD001 for the potential treatment of AL amyloidosisAdditional presentations to highlight data from preclinical and quality of life studies showcases commitment to advancing new therapies for multiple forms of amylo...
May 19, 2016
DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that data from multiple quality of life studies in patients with AL amyloidosis will be highlighted...
May 9, 2016
DUBLIN, Ireland, May 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its Phase 1 single ascending dose study of PRX003 in healthy volunteers wil...
May 3, 2016
Net cash used in operating and investing activities was $25.4 million in the first quarter; strong quarter-end cash position of $474.3 million, including net proceeds of $128.6 million raised through January 2016 public equity offering, supports advancement of multiple clinical development programs...
Mar 16, 2016
DUBLIN, Ireland, March 16, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced the publication of preclinical data demonstrating that the company's conformati...
Feb 29, 2016
DUBLIN, Ireland, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that preclinical data from its PRX003 program will be presented at the American Academy of Allergy...
Feb 24, 2016
DUBLIN, Ireland, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of David B. McNinch as Chief Commercial Officer. ...
Feb 18, 2016
Net cash used in operating and investing activities was $20.7 million in the fourth quarter and $63.8 million for the full year of 2015; net proceeds of $128.6 million raised through January 2016 public equity offering added to $370.6 million year-end cash position provides strong foundation to advance a robust clinica...
Feb 9, 2016
DUBLIN, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that interim data from its Phase 1/2 clinical study of NEOD001 in patients with AL Amyloidosis and persiste...
Feb 4, 2016
DUBLIN, Ireland, Feb. 04, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2015 financial results on Thursday, February ...
Feb 1, 2016
DUBLIN, Ireland, Feb. 01, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will present and participate in two upcoming meetings:...
Jan 7, 2016
DUBLIN, Ireland, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it priced an underwritten public offering of 2,250,000 of its ordinary shares at a price to t...
Jan 5, 2016
DUBLIN, Ireland, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that it has commenced an underwritten public offering of 2,250,000 of its ordinary shares. All of ...
Dec 1, 2015
DUBLIN, Ireland., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will participate in two upcoming investor...
Nov 5, 2015
DUBLIN, Ireland, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that new preclinical data related to its NEOD001 program, health-related quality of life data in p...
Nov 4, 2015
DUBLIN, Nov. 04, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of the senior management team will present and participate in the 2015 Credit Sui...
Nov 2, 2015
Net cash used in operating activities was $16.9 million in the third quarter and $42.8 million for first nine months of 2015; quarter-end cash position of $387.8 million provides solid runway for continued advancement of multiple programsRecently, announced plans to initiate PRONTO, a global t...
Oct 15, 2015
Accelerates Development Timeline and Potential Path to PatientsProthena to Host Investor Conference Call and Webcast Today at 4:30 p.m. ET DUBLIN, Ireland, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical ...
Sep 22, 2015
DUBLIN, Ireland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of the senior management team will present and participate in investor meetings at the Lade...
Aug 4, 2015
Net cash used in operating activities was $11.1 million in the second quarter and $25.9 million for first six months of 2015; completion of successful public equity offering netting $131.4 million strengthened quarter-end cash position of $402.4 million providing solid runway for continued advancement of multiple programsDrs. Morie A. Gertz (Mayo C...
Jun 29, 2015
DUBLIN, Ireland, June 29, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced the appointment of Anders Härfstrand, MD, PhD, to its Board of Directors. "Anders' wealth...
Jun 17, 2015
PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives MetDose- and Time-Dependent, Statistically Significant Reduction in Free Serum Alpha-Synuclein within One Hour of PRX002 AdministrationData Presented in Late Breaking Poster Session at 19th International Congress of Parkinson's Disease and Movement Disorders (Abstrac...
Jun 16, 2015
DUBLIN, Ireland, June 16, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that members of the senior management team will present and participate in investor meetings at th...
Jun 12, 2015
DUBLIN, Ireland, June 12, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dr. Michaela Liedtke of Stanford University School of Medicine presented data from the ongoin...
Jun 12, 2015
72% of Survey Respondents had AL Amyloidosis54% of Patients with AL Amyloidosis Reported Difficulty Tolerating Current Off-Label TreatmentsDiagnosis of AL Amyloidosis is Often Missed by Cardiologists and Non-Specialist Hematologists49% of Patients Required Visits to At Least Four Physicians and 34% Required Visits to At Least Five Physicians Before...
Jun 9, 2015
DUBLIN, Ireland, June 9, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced the successful first human dosing in a Phase 1 clinical trial of its proprietary protein immunother...
Jun 8, 2015
Investor Conference Call and Webcast to be Held Wednesday, June 17, 2015 at 5:30 p.m. EDT DUBLIN, Ireland, June 8, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that ...
Jun 2, 2015
Positive NEOD001 Phase 1/2 Results Further Support the Design of The VITAL Amyloidosis Study, a Global Phase 3 Registrational TrialIncrease in Best Response Rate to 60% in 15 Renal-Evaluable PatientsIncrease in Best Response Rate to 57% in 14 Cardiac-Evaluable Patients Results Consistent with Proposed Mechanism of Action, Indicating NEOD001 Neutral...
May 21, 2015
DUBLIN, Ireland, May 21, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dr. Michaela Liedtke will give an oral presentation of clinical data from its ongoing Phase 1/...
May 13, 2015
Investor Conference Call and Webcast to be Held Tuesday, June 2, 2015 at 3:00 p.m. EDT DUBLIN, Ireland, May 13, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that upd...
May 5, 2015
Net cash used in operating activities was $14.7 million in the first quarter; net proceeds of $131.4 million raised through April 2015 public equity offering added to $279.9 million quarter-end cash position provide solid runway for continued advancement of multiple programsReported positive results from a Phase 1 single ascending dose study of PRX...
May 4, 2015
NEW YORK and DUBLIN, Ireland, May 4, 2015 (GLOBE NEWSWIRE) -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced an agreement under wh...
Apr 28, 2015
DUBLIN, Ireland, April 28, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that members of the senior management team will present and participate in investor meetings at t...
Apr 23, 2015
DUBLIN, Ireland, April 23, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will participate on a...
Apr 8, 2015
DUBLIN, Ireland, April 8, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that it priced an underwritten public offering of 3,300,000 of its ordinary shares at a price to t...
Apr 6, 2015
DUBLIN, Ireland, April 6, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that it has commenced an underwritten public offering of 3,300,000 of its ordinary shares. All of ...
Mar 19, 2015
All Doses of PRX002 Found to be Safe and Well Tolerated, Meeting Primary Objective of Phase 1 Single Ascending Dose StudyResults of Study Demonstrate Rapid and Dose-Dependent Reduction of Free Serum Alpha-Synuclein, Potential Disease-Causing Protein in Parkinson's DiseaseDUBLIN, Ireland, March 19, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (...
Mar 5, 2015
Net cash used in operating activities was $12.5 million in the fourth quarter and $0.7 million for the full year of 2014; year-end cash position of $293.6 million provides solid runway for continued advancement of multiple programsInitiated The VITAL Amyloidosis Study, a global Phase 3 registrational trial for NEOD001, based on positive results fro...
Feb 19, 2015
DUBLIN, Ireland, Feb. 19, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that it will report its fourth quarter and full year 2014 financial results on Thursday, March 5, ...
Feb 18, 2015
DUBLIN, Ireland, Feb. 18, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced today that Gene Kinney, PhD, the Company's Chief Scientific Officer and Head of Research and Development...
Dec 15, 2014
First Investigational Immunotherapy for AL Amyloidosis to Receive FDA Fast Track DesignationFollows Recent Initiation of The VITAL Amyloidosis Study, a Global Phase 3 Registrational Trial of NEOD001 for Patients with AL Amyloidosis DUBLIN, Ireland, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical b...
Dec 8, 2014
DUBLIN, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve amyloid or cell adhesion, announced that Tran Nguyen, the Company's Chief Financial Officer,...
Dec 2, 2014
New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable PatientsNew Data Show 43% Best Response Rate in 14 Renal-Evaluable PatientsCardiac and Renal Biomarker Responses of Single-Agent NEOD001-Treated Patients Compare Favorably with Historical Data in Patients with AL AmyloidosisNEOD001 Continues to be Safe and Well-Tolerated, with N...
Nov 3, 2014
Net cash used in operating activities was $12.3 million in the third quarter, while quarter-end cash position of $306.2 million provides solid runway for advancement of multiple programs  Initial indication for PRX003 targeted to psoriasis to leverage rapid proof-of-biology and inform future clinical pathway  NEOD001, for the treatment ...
Aug 26, 2014
Data to be Presented by Dr. Timo Siepmann on the Discovery of a Potential New Non-Invasive Biomarker for Parkinson's DiseaseResults Extend Prior Research Confirming Skin Response (Goose Bump) Deficit in Patients With Early Stage Parkinson's Disease DUBLIN, Ireland, Aug. 26, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clin...
Aug 18, 2014
DUBLIN, Ireland, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today announced that Dale Schenk, PhD, the Company...
Aug 4, 2014
Completion of successful public equity offering netting $102.5 million and net cash provided by operating activities of $6.2 million in second quarter 2014 contributed to strengthen cash position to $303.9 millionPromising interim results of ongoing Phase 1 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction presented ...
Jul 31, 2014
First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 StudyTrial Designed to Evaluate Safety, Tolerability, Pharmacokinetics and ImmunogenicityMultiple Biomarkers to be Assessed DUBLIN, Ireland, July 31, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the d...
Jun 25, 2014
DUBLIN, Ireland, June 25, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it has priced an underwritten...
Jun 23, 2014
DUBLIN, Ireland, June 23, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it has commenced an underwrit...
May 27, 2014
DUBLIN, Ireland, May 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that Dale Schenk, PhD, the Company'...
May 5, 2014
Encouraging cardiac biomarker responses from ongoing Phase 1 of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction presented at ISAAdditional Phase 1 data updates of NEOD001 expected later this yearExpect to initiate Phase 2/3 clinical trial of NEOD001 in the fourth quarter of 2014Dosing of first healthy subject in Phase 1 PRX...
May 1, 2014
DUBLIN, May 1, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that it will host a live webcast and conferen...
Apr 30, 2014
DUBLIN, Ireland, April 30, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the appointment of Arthur W. ("Bi...
Apr 23, 2014
NEOD001 appears generally safe, well-tolerated, has acceptable pharmacokinetic properties and no immunogenicity at studied dose levelsNo dose limiting toxicities have been observedEight of nine evaluable patients with AL amyloidosis with cardiac involvement either achieved responses (N=5) or were considered stable (N=3)Additional Phase 1 data updat...
Apr 8, 2014
Entering clinic triggers $15 million milestone payment from Roche DUBLIN, Ireland, April 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfoldin...
Mar 18, 2014
DUBLIN, March 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that an abstract (Abstract #PB-48) reviewi...
Mar 6, 2014
DUBLIN, Ireland, March 6, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, today reported financial results for the fourth qu...
Mar 3, 2014
DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the promotion of Tara Nickerson, P...
Feb 18, 2014
Prothena to participate in February investor healthcare conferences, February 24-25DUBLIN, Ireland, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve prot...
Feb 3, 2014
DUBLIN, Ireland, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today the closing of a previously announ...
Jan 29, 2014
DUBLIN, Ireland, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today the pricing of an underwritten pu...
Jan 27, 2014
DUBLIN, Ireland, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today the underwritten public offering ...
Jan 23, 2014
DUBLIN, Ireland, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding and cell adhesion, announced today that, pursuant to its License, De...
Dec 30, 2013
DUBLIN, Ireland, Dec. 30, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today announced that it was selected for addition to the NASDAQ Biotechnology Inde...
Dec 11, 2013
Prothena to receive up to $600 million, inclusive of upfront payment and near-term clinical milestone totaling $45 million, as well as 30 percent of U.S. profits, and up to double-digit royalties on ex-U.S. net sales Prothena to host conference call/webcast today (December 11) at 4:30 p.m. Eastern Time BASEL, Switzerland and DUBLIN, Irelan...
Nov 12, 2013
DUBLIN, Ireland, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today reported financial results for the third quarter and nine months ended Septe...
Oct 28, 2013
DUBLIN, Ireland, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of a broad range of diseases, today announced that it will host its Research and Development Day on Monday, Nove...
Oct 3, 2013
DUBLIN, Ireland, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that it has priced an underwritten public offering of 5,910,000 of its ordinary shares at a...
Aug 12, 2013
DUBLIN, Ireland, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today reported financial results for the second quarter and six months ended June 30, 2013 and provid...
Aug 7, 2013
DUBLIN, Ireland, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Gene Kinney, PhD, the Company's Chief Scientific Officer and Head of Research and Deve...
Jul 22, 2013
DUBLIN, Ireland, July 22, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Dennis J. Selkoe, MD to its Board of Directors. Dr. Selkoe joins e...
Jul 1, 2013
DUBLIN, Ireland, July 1, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will be present...
Jun 17, 2013
DUBLIN, Ireland, June 17, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that the trading of its ordinary shares will be included in the Russell Global Index when R...
May 29, 2013
DUBLIN, Ireland, May 29, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will be present...
May 14, 2013
DUBLIN, Ireland, May 14, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today reported financial results for the first quarter ended March 31, 2013 and provided an update on...
Apr 23, 2013
DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the successful first patient dosing in a Phase 1 clinical trial of its antibody ther...
Mar 28, 2013
Company Advances Pipeline With Strong Capital Position Following 2012 Spin-OffNEOD001 to Enter Clinic in Early 2013 DUBLIN, Ireland, March 28, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of disea...
Mar 25, 2013
DUBLIN, Ireland, March 25, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that two senior executives have joined the Company.  Prothena has appointed Martin Koller, MD, MPH ...
Mar 21, 2013
DUBLIN, Ireland, March 21, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that it will report its fourth quarter and full year 2012 financial results on Thursday, March 28, ...
Mar 19, 2013
DUBLIN, Ireland, March 19, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Christopher S. Henney, PhD to its board of directors and Audit, Compensation, an...
Feb 27, 2013
DUBLIN, Ireland, Feb. 27, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that the European Medicines Agency (EMA) granted orphan designation for its lead program, NEOD001, f...
Feb 13, 2013
DUBLIN, Ireland, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that its President and Chief Executive Officer, Dale Schenk, Ph.D., will ring the NASDAQ Stock Marke...
Jan 7, 2013
DUBLIN, Ireland, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the appointment of Richard T. Collier and Shane Cooke to its board of directors. Mr. Collier and Mr. ...
Dec 21, 2012
DUBLIN, Ireland, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced the successful completion of its separation and share distribution, finalizing the transition to its...
Nov 13, 2012
South San Francisco, CA, November 13, 2012 – Prothena Corporation, a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, today announced that the company’s management team will present a company overview at the Lazard Capital Markets 9th Annual H...
Aug 13, 2012
Creates two independent, unique companies Transaction aligns assets, timelines, and risk/reward Elan to become immediately profitable and a high growth company Targeting $1.00 earnings per share by 2015 with new business construct...
Page:
...
Next Last
 
= add release to Briefcase